Philadelphia, PA, January 17, 2014 – ERT, a leading global solution provider for high-quality patient safety and efficacy endpoint data collection, today opened registration for PROFICIENCY 2014: Optimizing Patient-Centric Endpoints. The educational conference is being held April 8-10, 2014 in Naples, FL. Complete conference information, including program agenda confirmed faculty, and registration can be found at http://www.ERT.com/clinical/resources/seminars.
PROFICIENCY 2014: Optimizing Patient-Centric Endpoints is ERT’s 7th annual conference on the effective use of Clinical Outcome Assessments (COAs) in clinical research. This year’s conference will focus on scientific, regulatory, and commercial perspectives of COAs that can be used as direct measures of treatment benefit, including patient-reported symptoms and functioning. The 2-day event features interactive sessions, case studies, and short courses on implementing effective COA and electronic COA (eCOA) strategies throughout the drug development lifecycle.
„Biopharmaceutical researchers are increasingly expanding their views on the value of COAs in clinical development programs,“ said Dr. Chad Gwaltney, Senior Director, Consulting Services at ERT. „Many have evolved their approach from ‚Should we use COAs?‘ to ‚How can we get the most out of our COA data throughout the product lifecycle?‘ PROFICIENCY 2014 will reflect these trends and answer researchers‘ questions about optimizing their patient-centric research through the effective use of COA-based endpoints.“
The faculty for PROFICIENCY is comprised of ERT scientists and regulatory experts and leading pharmaceutical, regulatory, and industry experts, including this sampling of confirmed speakers:
Richard Levy, M.D. – Executive Vice President, Chief Drug Development and Medical Officer, Incyte Corporation
John H. Powers III, M.D. FACP FIDSA – Associate Clinical Professor of Medicine, School of Medicine, George Washington University & University of Maryland
Debra Silberg, M.D., Ph.D., – Senior Director, Clinical Development, Shire Pharmaceuticals
Arthur Stone, Ph.D. – Distinguished Professor and Vice Chairman, Dept. of Psychiatry and Behavioral Science, State University of New York (SUNY) at Stony Brook University & Senior Scientific Consultant, ERT
„We have several compounds in our pipeline where the primary outcome is a PRO measure,“ said 2013 PROFICIENCY attendee, Vipan Sood, Director HEOR, Mitsubishi-Tanabe Pharma America. „PROFICIENCY is an excellent conference to learn from the mistakes and successes of others, which will help us to promote our products successfully as we move forward.“
ERT is offering 30% off of conference fees for attendees who register before Feb.15, 2014. For more information and to register, visit http://www.ERT.com/clinical/resources/seminars.
About ERT ERT (http://www.ert.com) is a leading provider of high-quality patient safety and efficacy endpoint data collection solutions for use in clinical drug development. ERT delivers a combination of technology, services, and consulting that increase the accuracy and reliability of patient data and improve the efficiency of the clinical development process throughout the product lifecycle. ERT delivers the most widely deployed solutions in centralized cardiac safety, respiratory services, suicide risk assessment and Clinical Outcome Assessments (COAs) – which includes patient, clinician, and observer reported outcomes. By efficiently integrating these solutions through a system built upon a scientific and regulatory foundation, ERT collects, analyzes, and delivers safety and efficacy data critical to the approval, labeling, and reimbursement of pharmaceutical products. ERT is a global organization with headquarters in Philadelphia, PA and offices throughout the U.S., U.K., Japan, and Germany.
Press Contact:
Christine Tobin
ERT
Philadelphia, PA
+1 (412) 719-4568